Identification of an optimal absolute lymphocyte count before bispecific antibody therapy for large B-cell lymphoma: A collaborative US bispecific consortium Study
Kunhwa Kim(The University of Texas MD Anderson Cancer Center), Ajay Major(University of Colorado Cancer Center), Zhouxuan Li(The University of Texas MD Anderson Cancer Center), Geoffrey Shouse(City Of Hope National Medical Center), Amrita Chauhan(Unknown), Yazeed Sawalha(Cleveland Clinic), Steven M. Bair(University of Colorado Cancer Center), Shakthi Bhaskar(Vanderbilt University Medical Center), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Allison M. Bock(Mayo Clinic), Paolo Strati(The University of Texas MD Anderson Cancer Center), Amy Ayers(The University of Texas MD Anderson Cancer Center), Reid W. Merryman(Harvard University), Narendranath Epperla(University of Utah), Jennifer L. Crombie(Dana-Farber Cancer Institute), Matthew A. Lunning(University of Nebraska Medical Center), Wei Qiao(The University of Texas MD Anderson Cancer Center), Lorenzo Falchi(Memorial Sloan Kettering Cancer Center), Swetha Kambhampati(City Of Hope National Medical Center), Andrew Jallouk(Vanderbilt University Medical Center), Omnia Farahat(The University of Texas MD Anderson Cancer Center), Zachary Hunzeker(The University of Texas MD Anderson Cancer Center)
Cited by 0
Related Papers
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|484